A Rising Star in Rare Disease: Roivant’s Lisraya

For decades, the standard of care for dermatomyositis was chronic steroids and off-label immunosuppressants. Blunt instruments for a disease that devastates skin and muscle alike, and that carries a mortality rate estimated around 10%. On August 27, that era ended.

What Just Happened

The FDA approved Lisraya (brepocitinib), a once-daily 30 mg pill developed by Priovant Therapeutics, a subsidiary of Roivant Sciences (Nasdaq: ROIV). It is the first oral targeted therapy ever approved specifically for dermatomyositis in adults. The drug was commercially available immediately after clearance, a launch cadence that signals commercial urgency.

Lisraya is a first-in-class TYK2/JAK1 inhibitor, originally licensed from Pfizer. It works by suppressing pathogenic cytokines at the root of DM’s inflammatory cascade rather than broadly hammering the immune system. The distinction matters clinically. In the Phase 3 VALOR trial, a large and long placebo-controlled study in dermatomyositis, brepocitinib 30 mg delivered a 15.3-point greater improvement in mean Total Improvement Score at Week 52 versus placebo (P<0.001), meeting its primary endpoint and all nine key secondary endpoints. Nearly twice as many treated patients were able to taper background corticosteroids compared to those on placebo.

The Addressable Population

Dermatomyositis is classified as rare, but the numbers are not trivial. Diagnosed prevalent cases in the United States were estimated around 38,500 in 2023. Because DM is chronic, patients stay on therapy for years or potentially for life. That structural feature transforms even a moderate penetration rate into a durable revenue base.

Priovant set the list price at $35,000 per 30-day supply, or roughly $420,000 annually. Leerink Partners had modeled $350,000 as the likely entry point; management priced above that. Apply a conservative 20% net penetration of the diagnosed pool, assume typical managed care discounts bring net revenue to 60% of list, and the DM indication alone could support peak annual revenues approaching $1 billion. Leerink itself had modeled the drug reaching $4.2 billion in combined revenue by fiscal 2032 if approvals follow in three further rare conditions.

Why Brepocitinib Is Not a One-Disease Molecule

That pipeline expansion is already underway. Phase 3 data in non-infectious uveitis are expected in the second half of 2026. A Phase 3 study in cutaneous sarcoidosis, which received FDA Breakthrough Therapy Designation after strong Phase 2 results, has enrolled its first patients, with topline data anticipated in 2028. Priovant also launched a Phase 2b/3 study in lichen planopilaris in early 2026, extending brepocitinib’s footprint to a fourth indication, each one a disease with few or no approved therapies.

Roivant’s balance sheet provides the runway to see these through. As of June 30, 2026, the company held about $3.8 billion in cash, cash equivalents, and marketable securities. Separately, Moderna made an aggregate $950 million noncontingent lump sum payment to Arbutus and Genevant on July 8, 2026 under an intellectual property settlement. Cash runway into profitability was management’s stated posture entering this launch.

Risks Worth Naming

The boxed warning on Lisraya includes serious infections, increased all-cause mortality, malignancies, major adverse cardiovascular events, and thrombosis, standard for the JAK inhibitor class but a real consideration for prescribers weighing alternatives. Payer negotiations will determine how quickly net pricing lands, and a rare disease specialty distribution model through a limited pharmacy network concentrates access risk. Competitors are watching; any label restriction or post-market signal could slow uptake.

The pipeline, while broad, carries binary risk at each Phase 3 readout. The NIU data expected in the second half of 2026 will be the next inflection point for the stock.

The Bigger Picture

Roivant’s model has always been to build focused, indication-specific subsidiaries around validated biology, then compound the asset across adjacent diseases. Brepocitinib’s DM approval is the proof of concept made commercial. The drug beat placebo on every endpoint in a large dermatomyositis trial, launched immediately after approval, and carries a price that indicates management’s confidence in payer willingness to cover it.

For investors who dismissed Roivant as a pre-revenue holding company, the math just changed. Lisraya is on the market now. Revenue starts accruing this quarter. And there are at least three more shots on goal from the same molecule still ahead.

ROIV may be worth a closer look before the next readout narrows the opportunity.